David M. Parham
Researcher
Also affiliated: University of Nebraska–Lincoln (1999); University of Southern California (2013–2024); Western University (2024); Prisma Health (2010); Baptist Memorial Hospital (1989–1999); Manpower Demonstration Research Corporation (2000); Boston Children's Hospital (2015); St. Joseph Hospital (1989); Seattle Children's Hospital (2007–2015); Children's Medical Center (1990); National Institutes of Health (1999); Arkansas Children's Hospital (1997–2008); Nebraska Medical Center (2007); St. Jude Children's Research Hospital (1982–2008); Nationwide Children's Hospital (2000–2013); Mayo Clinic (1999–2000); Children’s Minnesota - St. Paul Hospital (2018); Memorial Sloan Kettering Cancer Center (1982–2000); Children's Hospital of Los Angeles (2010–2025); Janssen (Belgium) (2018); Pediatric Oncology Group (1994); Johns Hopkins University (1999); Emory University (2000); University of Tennessee Health Science Center (1977–2008); Eli Lilly (United States) (2018); University of Dundee (1988–1993); Pfizer (United States) (2018); King Abdulaziz University (2024); University of Washington (2013–2015); Oklahoma City University (2011); University of Arkansas Medical Center (2006); Royal Bournemouth Hospital (1994–2016); Keck Hospital of USC (2018); Perth Royal Infirmary (1991–1992); Inova Fairfax Hospital (2003); California Southern University (2014); Poole Hospital (1996); Saint Thomas Midtown Hospital (1992); Ninewells Hospital (1988–2008); Tianjin Medical University Cancer Institute and Hospital (2024); Edinburgh Royal Infirmary (1985); University Medical Center (2007); University Hospital Southampton NHS Foundation Trust (2023–2025); University of Oklahoma Medical Center (2011); Elekta (Switzerland) (2018); Yale University (1991); Fred Hutch Cancer Center (2015); Arkansas Cardiology (2021); Auguste-Viktoria-Klinik (1999); Mount Sinai Medical Center (1982); Southwestern Medical Center (2013); Los Angeles Medical Center (2015); GlaxoSmithKline (India) (2018); DiscoveryBioMed (United States) (2006); Mahindra and Mahindra Limited (India) (1998); Arcadia (2003); Seattle Children's Hospital (2013); Children's Hospital of Oklahoma (2008); Boehringer Ingelheim (India) (2018); Children's Medical Center (2013); University Pathologists (1995–1999); Cancer Research Center (2015); Children's Hospital of Pittsburgh (2007–2009); Children's Oncology Group (2003); Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust (1996); AstraZeneca (Poland) (2018); St. Joseph Medical Center in Tacoma (1989); Frontier Science & Technology Research Foundation, Inc. (2015); National Cancer Institute (1999–2013); Pediatrics and Genetics (2007); Baptist Hospital (1992); Children's Hospital & Medical Center (1999–2014); Boston Children's Museum (2022); Boehringer Ingelheim (Australia) (2018); Retina Research Foundation (1995); Data Power Decisions (United States) (1999); Memphis Health Center (1991); Le Bonheur Children's Hospital (1990–1992); Arkansas Department of Agriculture (2002); Children's Hospital (2022); S.P.E.C.I.E.S. (1994); OU Health (2011); University of Oklahoma Health Sciences Center (2003–2023); The Ohio State University (2013); Indiana University – Purdue University Indianapolis (1999); University of Nebraska Medical Center (2007–2013); Virginia Commonwealth University Medical Center (1992); University of Tennessee at Knoxville (1990–1999); The University of Texas Southwestern Medical Center (2013–2015); University of Oklahoma (2008–2011); University of Memphis (1995); Stanford University (2007)
Faculty Researcher
Upstream record may be merged OpenAlex, the source of these figures, lists 94 institutions in 12 countries for this author record — a pattern that usually means it combines several researchers with similar names. The totals above may include work by other people.
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
David M. Parham's research focuses on the pathology and molecular underpinnings of pediatric cancers, particularly rhabdomyosarcoma and other soft tissue sarcomas. His work investigates how advanced molecular methods are reshaping the diagnostic and therapeutic paradigms for these diseases. He has contributed to understanding the genetic spectrum of pediatric mesenchymal tumors, including studies on FGFR1 gene fusions and their overlap with other spindle cell neoplasms.
Parham's publications also address important clinical questions in pediatric oncology, such as the significance of lymph node metastases in non-rhabdomyosarcoma soft tissue sarcomas and the frequency of TP53 germline pathogenic variants in anaplastic rhabdomyosarcoma. He has also explored rare pediatric tumors, including Sertoli-Leydig cell tumors of the ovary and epithelioid sarcoma in the context of rhabdoid tumor predisposition syndrome. His work often involves large collaborative efforts, such as those within the Children's Oncology Group (COG).
With an h-index of 81 and over 21,000 citations across more than 460 publications, Parham is recognized as a highly cited researcher. His scholarship is dedicated to advancing the understanding and treatment of pediatric solid tumors through detailed pathological analysis and the integration of molecular diagnostics.
Metrics
- h-index: 82
- Publications: 462
- Citations: 21,328
Selected Publications
-
Pediatric Embryonal Rhabdomyosarcoma: An Integrated Study of Clinicopathological Features, Pan-cancer Targeted Next-generation Sequencing, and Chromosomal Microarray Analysis from a Single Institution (2025)
Collaboration Network
Top Collaborators
- Pediatric Embryonal Rhabdomyosarcoma: An Integrated Study of Clinicopathological Features, Pan-cancer Targeted Next-generation Sequencing, and Chromosomal Microarray Analysis from a Single Institution
- Pediatric Embryonal Rhabdomyosarcoma: An Integrated Study of Clinicopathological Features, Pan-cancer Targeted Next-generation Sequencing, and Chromosomal Microarray Analysis from a Single Institution
- Pediatric Embryonal Rhabdomyosarcoma: An Integrated Study of Clinicopathological Features, Pan-cancer Targeted Next-generation Sequencing, and Chromosomal Microarray Analysis from a Single Institution
- Pediatric Embryonal Rhabdomyosarcoma: An Integrated Study of Clinicopathological Features, Pan-cancer Targeted Next-generation Sequencing, and Chromosomal Microarray Analysis from a Single Institution
- Pediatric Embryonal Rhabdomyosarcoma: An Integrated Study of Clinicopathological Features, Pan-cancer Targeted Next-generation Sequencing, and Chromosomal Microarray Analysis from a Single Institution
- Pediatric Embryonal Rhabdomyosarcoma: An Integrated Study of Clinicopathological Features, Pan-cancer Targeted Next-generation Sequencing, and Chromosomal Microarray Analysis from a Single Institution
- Pediatric Embryonal Rhabdomyosarcoma: An Integrated Study of Clinicopathological Features, Pan-cancer Targeted Next-generation Sequencing, and Chromosomal Microarray Analysis from a Single Institution
Similar Researchers
Based on overlapping research topics